H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $32 from $27 and keeps a Buy rating on the shares after a U.S. District court upheld the validity of the company’s ‘721 patent. Given the exclusivity till 2038, Acadia might not have any generic competition, allowing the company to have pricing control along with minimization of payer leverage, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia court ruling alleviates overhang for Nuplazid, says RBC Capital
- Acadia confirms court ruling in favor of Nuplazid formulation patent
- ACADIA Pharmaceuticals: Strengthened Patent Position and Growth Prospects Drive Buy Rating
- Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer
- Acadia Nuplazid patent ruling removes ‘key overhang,’ says BMO Capital